Tissue Sodium in Patients With Psoriasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

56 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-07-01

Study Completion Date

2019-09-17

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Sodium can be buffered in the skin, which mechanism is altered during aging and in certain diseases such as hypertension. High salt environment can promote autoimmunity by expanding pathogenic IL-17 producing T helper (Th17) cells. Psoriasis is a relapsing and remitting inflammatory autoimmune disease affecting the skin and joints and involves proinflammatory Th17 cells. Here we tested the hypothesis if psoriatic skin has a higher sodium content in humans.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Assessment of Digital Imaging as a Tool for Diagnosing Psoriasis, Hand Rashes and Unusual Moles

NCT00005781

Dermatitis Nevus Psoriasis

COMPLETED

Nephrogenic Systemic Fibrosis (NSF): Analysis of Tissue Gadolinium Levels

NCT01014754

Nephrogenic Systemic Fibrosis Nephrogenic Fibrosing Dermopathy

COMPLETED

Diffuse Cutaneous Scleroderma (DSSc) SFDI Study

NCT07090226

Systemic Scleroderma Diffuse Cutaneous Scleroderma

RECRUITING NA

Distal Erosions and Nail Psoriasis

NCT02813720

Psoriatic Arthritis

UNKNOWN

Coagulopathy of Immunodermatologic Diseases

NCT06037187

Autoimmune Bullous Dermatosis

RECRUITING

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The cytokine interleukin-17A (IL-17A) is a crucial player in the pathogenesis of the autoimmune disease of psoriasis. This neutrophil recruiting cytokine is produced by IL-17A producing CD4+ T cells (Th17) and gamma/delta T cells of the skin and evokes an inflammation circuit finally leading to the classical clinical picture of psoriasis with hyper- and parakeratosis, erythema, scaling and neutrophil abscess formation.

Besides genetic factors, lifestyle factors are relevant and decide if an autoimmune disease becomes manifest. It was shown previously that increased salt (sodium chloride, NaCl) concentrations boost the induction of murine and human Th17 cells. However, more - and also clinical - studies are needed to understand the correlation between salt content and IL-17A in autoimmune diseases.

This study investigates the hypothesis if skin sodium content in human psoriasis is increased in order to get further insight into the IL-17A-salt-interplay.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Psoriasis Vulgaris Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Healthy subjects

those without a condition

23Na Magnetic resonance imaging

Intervention Type DIAGNOSTIC_TEST

Measurement of skin sodium content by non-invasive 23Na Magnetic resonance imaging.

Psoriasis patients

those with a condition

23Na Magnetic resonance imaging

Intervention Type DIAGNOSTIC_TEST

Measurement of skin sodium content by non-invasive 23Na Magnetic resonance imaging.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

23Na Magnetic resonance imaging

Measurement of skin sodium content by non-invasive 23Na Magnetic resonance imaging.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age: 18-80
* Body mass index (BMI) 18.5- 40 kg/m2
* Glomerular filtration rate \>60 ml/min/1.73m2

Exclusion Criteria

* Diagnosed or treated hypertension and/or blood pressure above 140/90 at screening
* Palpable peripheral oedema during phyisical examination at screening
* Any type of diabetes mellitus and/or HgbA1c\>6.5% at screening
* Subjects with a thyroid-stimulating hormone \>4.2 mU/L at screening
* Psoriasis patients treated with systemic corticosteroids, chemotherapy agent (methothrexate) or with any kind of biologics/biosimilars
* Subjects with acute disease
* Pregnant or lactating women
* Metal or medical device implant in the body
* Tattoo on the lower extremities
* Subjects with a history of drug or alcohol abuse
* Subjects who are legal incapacitated or their circumstances do not enable the patient to fully understand the nature, significance and scope of this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No